Literature DB >> 9195529

Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease.

M Wong1, E D Silverman, E N Fish.   

Abstract

OBJECTIVE: Patients with Kawasaki disease mount an immune response directed to their abnormally stimulated vascular endothelium, that is associated with vascular inflammation and injury and a predisposition to arterial aneurysm formation. This suggests that specific pro-inflammatory cytokines may mediate these hyperreactive responses. The selective chemoattractant and activation effects of chemokines on lymphocytes identifies them as potential candidates in mediating selective inflammatory processes in Kawasaki disease. We examined peripheral blood from patients with Kawasaki disease for chemokine gene expression.
METHODS: Consecutive samples from 14 patients during the acute, subacute, and convalescent phases of their illness were collected and elaborated for RANTES, macrophage inflammatory protein-1 beta (MIP-1 beta) and monocyte chemotactic protein-1 (MCP-1) expression.
RESULTS: RANTES and MCP-1 gene expression levels were significantly elevated in 12 of the 14 patients, and MIP-1 beta gene expression was elevated in 13 of the 14 patients. There was no obvious correlation between clinical phase of the disease and chemokine expression level, yet elevated expression levels were detected in all phases, including the convalescent phase, when laboratory evidence of lymphocyte activation has been shown to return to normal. Serial samples showed persistence or increased expression of chemokine genes into the convalescent phase in patients with coronary artery lesions.
CONCLUSION: Chemokine mediated inflammatory events may persist in the convalescent phase of Kawasaki disease and may contribute to further risk of vascular endothelial cell injury, specifically coronary aneurysm formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195529

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

1.  Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease.

Authors:  W B Breunis; M H Biezeveld; J Geissler; I M Kuipers; J Lam; J Ottenkamp; A Hutchinson; R Welch; S J Chanock; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Urotensin 2 in Kawasaki disease pathogenesis.

Authors:  Cassidy Y Huang; Jane C Burns; Chisato Shimizu
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

3.  Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1.

Authors:  D L Tuttle; J K Harrison; C Anders; J W Sleasman; M M Goodenow
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.

Authors:  Eisuke Suganuma; Fumio Niimura; Shinichi Matsuda; Toshiko Ukawa; Hideaki Nakamura; Kaori Sekine; Masahiko Kato; Yuji Aiba; Yasuhiro Koga; Kuniyoshi Hayashi; Osamu Takahashi; Hiroyuki Mochizuki
Journal:  Pediatr Res       Date:  2016-12-20       Impact factor: 3.756

5.  Production of chemokines in Kawasaki disease, Henoch-Schönlein purpura and acute febrile illness.

Authors:  Hyo Seok Chung; Hyo Young Kim; Hee Sun Kim; Hee Jung Lee; Ji Hyun Yuh; Eun Sil Lee; Kwang Hae Choi; Young Hwan Lee
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

6.  Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.

Authors:  Manju Mamtani; Tomoyo Matsubara; Chisato Shimizu; Susumu Furukawa; Teiji Akagi; Yoshihiro Onouchi; Akira Hata; Akihiro Fujino; Weijing He; Sunil K Ahuja; Jane C Burns
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

Review 7.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

8.  Infliximab treatment in refractory Kawasaki syndrome.

Authors:  Meenakshi Girish; Girish Subramaniam
Journal:  Indian J Pediatr       Date:  2008-06-08       Impact factor: 1.967

9.  Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin.

Authors:  Masaru Miura; Kazuki Kohno; Hirotaka Ohki; Shigeki Yoshiba; Akinori Sugaya; Masaaki Satoh
Journal:  Eur J Pediatr       Date:  2008-01-04       Impact factor: 3.183

10.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.